Neurocrine Biosciences has randomised the first subject in its Phase II clinical trial of an investigational compound, NBI-1117568, in adult schizophrenia patients.

The multi-arm, placebo-controlled, multi-stage inpatient trial is designed to assess the safety, tolerability, efficacy, and pharmacokinetics of NBI-1117568.

Being carried out at 15 US centres, the trial will enrol nearly 200 adult subjects. 

Various active dose levels of NBI-1117568 will be analysed in the trial. 

The variation from baseline in the total Positive and Negative Syndrome Scale (PANSS) score to week six is the trial’s primary outcome measure. 

NBI-1117568 is a muscarinic M4 selective acetylcholine receptor agonist.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company had obtained the rights for developing the compound from Sosei Heptares.

A serious and complex ailment, schizophrenia has heterogeneous symptoms. 

Standard therapy approaches for the syndrome depend on the usage of antipsychotic medications linked to metabolic syndrome and neurologic symptoms.

Neurocrine Biosciences chief medical officer Eiry Roberts said: “Initiation of this Phase II study for NBI-1117568 brings forward a first-in-class, orally active, highly selective investigational M4 agonist as a potential treatment for schizophrenia, a serious and complex psychiatric syndrome impacting 0.5-1.0% of the US population and approximately 20 million people worldwide. 

“The differentiated profile of NBI-1117568 in terms of its selectivity as an M4 agonist may provide an opportunity for efficacy in treating the symptoms of psychosis, with a potentially different side effect profile.”

In December last year, the company reported that the Phase III KINECT-HD clinical trial of valbenazine met the primary goal of decreasing chorea severity in adult Huntington’s disease patients.